Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eloctate

Biogen Idec building

Biogen Idec’s haemophilia candidate faces US delay

FDA extends review of Alprolix

- PMLiVE

Novo Nordisk wins US approval for haemophilia treatment

NovoEight will be launched alongside MixPro device after gaining FDA licence

- PMLiVE

Baxter gets OK for BeneFix competitor in US

Rixubis becomes first new drug in its class in more than 15 years

Biogen Idec building

FDA starts review of Biogen Idec’s haemophilia A therapy

Could gain US approval by the first quarter of 2014

- PMLiVE

Biogen submits haemophilia drug for US approval

Step forward for its partnership with Swedish Orphan Biovitrum

- PMLiVE

Biogen Idec drops ALS drug dexpramipexole

Fails to achieve efficacy in phase III trial

- PMLiVE

Novo launches haemophilia tracking app

Will compete with similar apps from Pfizer, Baxter

- PMLiVE

Novo Nordisk files new haemophilia drug in EU, US

Seeks approval for turoctocog alfa shortly after vatreptacog alfa pulled

- PMLiVE

Novo drops late-stage haemophilia candidate vatreptacog alfa

Patients developed anti-drug antibodies during phase III clinical trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links